Skip to main content

Table 3 Cox risk regression in WHO grades II, III, and IV gliomas

From: Does epilepsy always indicate worse outcomes? A longitudinal follow-up analysis of 485 glioma patients

Variables

Groups

WHO grade II

 

WHO grade III

 

WHO grade IV

 
  

Univariate p-value

Multivariate p-value

Multivariate HR (95% CI)

Univariate p-value

Multivariate p-value

Multivariate HR (95% CI)

Univariate p-value

Multivariate p-value

Multivariate

HR (95% CI)

Epilepsy

Yes

0.565

-

-

0.362

-

-

0.040

0.000

0.46 (0.29–0.73)

No

Reference

-

-

Reference

-

-

Reference

Reference

Reference

Age

 

0.526

-

-

0.068

0.069

1.02 (1.00–1.04)

0.024

0.276

1.01 (0.99–1.02)

Gender

Female

Reference

-

-

Reference

-

-

Reference

-

-

Male

0.349

-

-

0.726

-

-

0.169

-

-

Location

Supratentorial

0.226

-

-

0.005

0.001

0.27 (0.12–0.60)

0.910

-

-

Subtentorial

Reference

-

-

Reference

Reference

Reference

Reference

-

-

Radiotherapy

Yes

0.547

  

0.009

0.005

0.40 (0.21–0.76)

0.000

0.006

0.46 (0.27–0.80)

No

Reference

Reference

Reference

Reference

Reference

Reference

Reference

Reference

Reference

Chemotherapy

Yes

0.571

  

0.019

0.467

1.31 (0.63–2.72)

0.000

0.038

0.56 (0.33–0.97)

No

Reference

Reference

Reference

Reference

Reference

Reference

Reference

Reference

Reference

Tumor number

Single

Reference

-

-

Reference

Reference

Reference

Reference

Reference

Reference

Multiple

0.951

-

-

0.000

0.001

2.92 (1.10–7.58)

0.000

0.000

2.45 (1.60–3.76)

Diagnosis

Primary

Reference

-

-

Reference

-

-

Reference

Reference

Reference

Recurrent

0.491

-

-

0.513

-

-

0.090

0.000

2.07 (1.36–3.16)

EOR

Total

Reference

-

-

Reference

Reference

Reference

Reference

Reference

Reference

Subtotal

0.504

-

-

0.686

0.160

0.61 (0.30–1.22)

0.011

0.006

1.64 (1.15–2.33)

Partial

0.003

-

-

0.003

0.033

2.44 (1.08–5.55)

0.003

0.014

2.44 (1.19–4.98)

One-year survival rate

Epilepsy

87.3%

  

65.8%

  

52.1%

  

No epilepsy

83.5%

  

55.0%

  

44.3%

  

Total

86.1%

  

58.9%

  

45.7%

  
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us